Loading...

Diffusion Pharmaceuticals

BST:DP8
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DP8
BST
$16M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. The last earnings update was 119 days ago. More info.


Add to Portfolio Compare Print
  • Diffusion Pharmaceuticals has significant price volatility in the past 3 months.
DP8 Share Price and Events
7 Day Returns
0%
BST:DP8
-5.1%
DE Biotechs
-0.7%
DE Market
1 Year Returns
-64.3%
BST:DP8
-13.7%
DE Biotechs
-10.5%
DE Market
DP8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Diffusion Pharmaceuticals (DP8) 0% 0% 9.9% -64.3% - -
DE Biotechs -5.1% -3% -6.6% -13.7% 62.2% -1.6%
DE Market -0.7% 4.5% 5.4% -10.5% 7.7% 11.8%
1 Year Return vs Industry and Market
  • DP8 underperformed the Biotechs industry which returned -13.7% over the past year.
  • DP8 underperformed the Market in Germany which returned -10.5% over the past year.
Price Volatility
DP8
Industry
5yr Volatility vs Market
Related Companies

DP8 Value

 Is Diffusion Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Diffusion Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €2.834999.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Diffusion Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Diffusion Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:DP8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-5.81
NasdaqCM:DFFN Share Price ** NasdaqCM (2018-12-13) in USD $4.87
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 22.64x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 18.74x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Diffusion Pharmaceuticals.

BST:DP8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:DFFN Share Price ÷ EPS (both in USD)

= 4.87 ÷ -5.81

-0.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Diffusion Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Diffusion Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Diffusion Pharmaceuticals's expected growth come at a high price?
Raw Data
BST:DP8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
6.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 18 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 276 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Diffusion Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Diffusion Pharmaceuticals's assets?
Raw Data
BST:DP8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $6.20
NasdaqCM:DFFN Share Price * NasdaqCM (2018-12-13) in USD $4.87
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 2.71x
Germany Market PB Ratio Median Figure of 569 Publicly-Listed Companies 1.76x
BST:DP8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:DFFN Share Price ÷ Book Value per Share (both in USD)

= 4.87 ÷ 6.20

0.79x

* Primary Listing of Diffusion Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Diffusion Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Diffusion Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Diffusion Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

DP8 Future Performance

 How is Diffusion Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Diffusion Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Diffusion Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Diffusion Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Diffusion Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:DP8 Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:DP8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 6.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 28.9%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 25%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:DP8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:DP8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 14 -13 1
2022-12-31 3 -20 1
2021-12-31 0 -14 1
2020-12-31 0 -15 2
2019-12-31 0 -15 2
2018-12-31 0 -22 2
BST:DP8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 -10 -20
2018-06-30 -12 -8
2018-03-31 -12 15
2017-12-31 -12 -3
2017-09-30 -11 -7
2017-06-30 -9 -15
2017-03-31 -10 -30
2016-12-31 -11 -18
2016-09-30 -12 -18
2016-06-30 -11 -14
2016-03-31 -9 -12
2015-12-31 -5 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Diffusion Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Diffusion Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:DP8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Diffusion Pharmaceuticals Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:DP8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.10 -2.10 -2.10 1.00
2022-12-31 -3.30 -3.30 -3.30 1.00
2021-12-31 -2.40 -2.40 -2.40 1.00
2020-12-31 -3.23 -2.55 -3.90 2.00
2019-12-31 -3.60 -3.60 -3.60 2.00
2018-12-31 -6.90 -6.30 -7.50 2.00
BST:DP8 Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -5.81
2018-06-30 -4.03
2018-03-31 10.67
2017-12-31 -3.15
2017-09-30 -8.76
2017-06-30 -21.45
2017-03-31 -43.75
2016-12-31 -26.44
2016-09-30 -31.69
2016-06-30 -32.31
2016-03-31 -38.43
2015-12-31 -38.47

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Diffusion Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Diffusion Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Diffusion Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

DP8 Past Performance

  How has Diffusion Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Diffusion Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Diffusion Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Diffusion Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Diffusion Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Diffusion Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Diffusion Pharmaceuticals Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:DP8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 -19.60 6.03 5.53
2018-06-30 -8.15 6.00 6.12
2018-03-31 14.51 6.14 5.91
2017-12-31 -2.62 6.19 5.09
2017-09-30 -6.64 5.93 5.46
2017-06-30 -14.97 8.43 4.69
2017-03-31 -30.09 6.28 4.96
2016-12-31 -18.04 8.59 6.30
2016-09-30 -18.19 8.87 6.06
2016-06-30 -14.17 5.23 5.99
2016-03-31 -11.70 5.93 5.50
2015-12-31 -6.72 2.52 3.88
2014-12-31 -3.53 1.36 1.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Diffusion Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Diffusion Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Diffusion Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Diffusion Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Diffusion Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

DP8 Health

 How is Diffusion Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Diffusion Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Diffusion Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Diffusion Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Diffusion Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Diffusion Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Diffusion Pharmaceuticals Company Filings, last reported 5 months ago.

BST:DP8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 20.91 0.00 11.02
2018-06-30 27.30 0.00 12.93
2018-03-31 29.72 0.55 16.20
2017-12-31 21.23 0.55 8.90
2017-09-30 6.36 0.55 11.24
2017-06-30 1.17 2.43 17.41
2017-03-31 -19.12 2.43 12.21
2016-12-31 9.18 2.43 1.55
2016-09-30 11.49 2.43 3.02
2016-06-30 14.03 0.55 3.01
2016-03-31 16.58 0.55 5.87
2015-12-31 -0.04 1.24 2.00
2014-12-31 -13.62 17.82 4.84
  • Diffusion Pharmaceuticals has no debt.
  • Diffusion Pharmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Diffusion Pharmaceuticals has sufficient cash runway for 1.1 years based on current free cash flow.
  • Diffusion Pharmaceuticals has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 14.2% each year.
X
Financial health checks
We assess Diffusion Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Diffusion Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

DP8 Dividends

 What is Diffusion Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Diffusion Pharmaceuticals dividends.
If you bought €2,000 of Diffusion Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Diffusion Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Diffusion Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:DP8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 333 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:DP8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Diffusion Pharmaceuticals has not reported any payouts.
  • Unable to verify if Diffusion Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Diffusion Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Diffusion Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Diffusion Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Diffusion Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Diffusion Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

DP8 Management

 What is the CEO of Diffusion Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Kalergis
COMPENSATION $510,524
AGE 69
TENURE AS CEO 3.2 years
CEO Bio

Mr. David G. Kalergis, JD, MBA, is Co-Founder of Diffusion Pharmaceuticals Inc.(formerly known as Diffusion Pharmaceuticals, LLC) and serves as its Chairman since January 2016 and Chief Executive Officer since 2004. Mr. Kalergis has overall responsibility for implementing the Diffusion's strategy, as established by the Board of Directors, as well as handling day-to-day operational matters. Mr. Kalergis served as the Chairman of the Board and Chief Executive Officer at Restorgenex Corporation since January 08, 2016. From 1986 to 1990, Mr. Kalergis served as the President and General Counsel of Designs Import/Export, Ltd. From 1991 to 1997, he served as General Counsel, Director of Business Development and Consultant to Pharmaceutical Research Associates, Inc. He serves as a Director of University of Virginia Gateway. He serves as an Director of Diffusion Pharmaceuticals Inc.(formerly known as Diffusion Pharmaceuticals, LLC.) since January 2016. Mr. Kalergis's duties at Gateway began on February 1, 1998. He serves on the board of the Virginia Piedmont Technology Council and the Computers4Klds Program. He served as a Director of Virginia National Bank and Virginia National Bankshares Corporation. From 1982 to 1986, he was associated with the New York law firm of Dewey, Ballantine, Bushby, Palmer & Wood. In 2002, he was awarded the Virginia Piedmont Technology Council's "Navigator" award for his leadership and contributions to the technology community and the region's economic development. He is a Member of the New York and Virginia State Bar Associations and is the author of The Role of the University in the Commercialization of Biotechnology (1981). Mr. Kalergis is a graduate of the Harvard Business School's Leadership and Strategy in Biotechnology and Pharmaceuticals program. Mr. Kalergis graduated from the University of Virginia with a BA degree in Psychology in 1970. In 1982, he received J.D. and M.B.A. degrees from the University of Virginia.

CEO Compensation
  • David's compensation has been consistent with company performance over the past year.
  • David's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Diffusion Pharmaceuticals management team in years:

2.5
Average Tenure
61
Average Age
  • The tenure for the Diffusion Pharmaceuticals management team is about average.
Management Team

David Kalergis

TITLE
Co-Founder
COMPENSATION
$511K
AGE
69
TENURE
3.2 yrs

John Gainer

TITLE
Co-Founder
COMPENSATION
$448K
AGE
79

Bill Hornung

TITLE
Chief Financial Officer
AGE
49
TENURE
0.5 yrs

Thomas Byrne

TITLE
General Counsel
AGE
61
TENURE
3.2 yrs

Kelly Hoy

TITLE
Director of Project Management

David Jones

TITLE
Senior Medical Advisor
AGE
55
TENURE
0.2 yrs

Harry Cook

TITLE
Vice President of Clinical Operations
TENURE
2.5 yrs

doug Gravatt

TITLE
Senior Consultant for Manufacturing

Brian Bollwage

TITLE
Senior Consultant - Regulatory Affairs
Board of Directors Tenure

Average tenure and age of the Diffusion Pharmaceuticals board of directors in years:

2.5
Average Tenure
68
Average Age
  • The average tenure for the Diffusion Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

John Gainer

TITLE
Co-Founder
COMPENSATION
$448K
AGE
79
TENURE
3.2 yrs

Robert Adams

TITLE
Director
COMPENSATION
$102K
AGE
68
TENURE
3.2 yrs

David Kalergis

TITLE
Co-Founder
COMPENSATION
$511K
AGE
69
TENURE
3.2 yrs

Mark Giles

TITLE
Lead Independent Director
COMPENSATION
$104K
AGE
63

Guy Chisolm

TITLE
Chairman of Scientific Advisory Board
TENURE
2.5 yrs

Alan Levin

TITLE
Director
COMPENSATION
$105K
AGE
56
TENURE
3.2 yrs

Gene Barnett

TITLE
Member of Scientific Advisory Board
TENURE
2.5 yrs

Connie Hess

TITLE
Member of Scientific Advisory Board
TENURE
2.5 yrs

William Hiatt

TITLE
Member of Scientific Advisory Board
TENURE
2.5 yrs

Karen Johnston

TITLE
Member of Scientific Advisory Board
TENURE
2.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Diffusion Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Diffusion Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

DP8 News

Simply Wall St News

DP8 Company Info

Description

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.

Details
Name: Diffusion Pharmaceuticals Inc.
DP8
Exchange: BST
Founded: 2001
$14,566,245
3,376,245
Website: http://www.diffusionpharma.com
Address: Diffusion Pharmaceuticals Inc.
1317 Carlton Avenue,
Suite 200,
Charlottesville,
Virginia, 22902,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM DFFN Common Stock Nasdaq Capital Market US USD 11. Mar 2008
BST DP8 Common Stock Boerse-Stuttgart DE EUR 11. Mar 2008
Number of employees
Current staff
Staff numbers
11
Diffusion Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/12 23:06
End of day share price update: 2018/12/13 00:00
Last estimates confirmation: 2018/12/10
Last earnings filing: 2018/11/13
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.